Chimerix Inc. (CMRX) is Trading Higher on Unusual Volume for December 21

Equities Staff |

Chimerix Inc. (CMRX) experienced unusually high volume on Dec. 21, as the stock gained 0.39% to a closing price of $35.91. The stock saw 828,558 shares trade hands over the course of the day on 4,326 trades. Given that the stock’s average daily volume over the last month has been 304,294 shares a day, this represents a pretty substantial spike over the norm.

Chimerix Inc. has a P/B ratio of 4.48. The stock has traded between $58.04 and $33.02 over the last 52-weeks, its 50-day SMA is now $37.95, and its 200-day SMA $42.46.

Chimerix Inc is a biopharmaceutical company that develops and commercializes oral antivirals. It has two compounds in clinical development: brincidofovir - CMX001 and CMX157.

Headquartered in Durham, NC, Chimerix Inc. has 123 employees and is currently under the leadership of CEO M. Michelle Berrey.

For a complete fundamental analysis analysis of Chimerix Inc., check out Equities.com’s Stock Valuation Analysis report for CMRX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

THE IMPORTANCE OF THE RUSSELL 3000

The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Kiwa Bio-Tech Products Group Corp

Kiwa Bio-Tech Products Group Corp develops, manufactures, distributes and markets, cost-effective and environmentally safe bio-technological products for agriculture in China.

Private Markets

Dropbox, Inc.

Dropbox is a service that allows their users to bring all photos, docs, and videos anywhere, and share them easily. Any file saved to Dropbox will automatically save to all…

Uber

Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…